Table 1 Baseline characteristics of eligible studies
ID [Name (Year)] | Country | Stage (UICC) | Methods | Time points | Markers | Positive rates n/N (%) | Endpoints | Hazard ratios | Quality |
|---|---|---|---|---|---|---|---|---|---|
Ikeguchi (2005) [23] | Japan | I-IV | RT-PCR | post-therapy | CEA | 25/55(45.5) | RFS/OS | data extrapolated | High |
Illert (2005) [24] | Germany | I-IV | RT-PCR | Pre-therapy | CK20 | 15/41(36.6) | OS(R0)a | data extrapolated | High |
Pre-therapy | CK20 | 13/29(44.8) | OS(R2/UR)a | data extrapolated | |||||
Wu (2006) [25] | China | I-IV | HTCMA | intra-therapy | CK19/CEA/MUC1/hTERT | 39/64(60.9) | OS | data extrapolated | High |
Uen (2006) [26] | China | I-IV | RT-PCR | intra-therapy | c-MET | 32/52(61.5) | OS | data extrapolated | High |
MUC1 | 37/52(71.2) | OS | data extrapolated | ||||||
Noworolska (2007) [27] | Poland | I-IV | FACS-ICC | Pre-therapy | CK8/18/19 | 31/57(54.4) | OS | data extrapolated | High |
Hiraiwa (2008) [28] | Japan | IV | CellSearch | intra-therapy | EpCAM/CK8/18/19 | 15/27(55.6) | OS | data extrapolated | Low |
Koga (2008) [29] | Japan | I-IV | RT-PCR | Pre-therapy | CK19 | 8/69(11.6) | OS | data extrapolated | High |
CK20 | 10/69(15.5) | OS | data extrapolated | ||||||
Yie (2008) [30] | China | I-IV | RT-PCR | Pre-therapy | survivin | 12/26(46.2) | RFS | reported in text | High |
Bertazza (2009) [31] | Italy | I-IV | RT-PCR | intra-therapy | survivin | 69/70(98.6) | OS | reported in text | High |
Arigami (2010) [32] | Japan | I-IV | RT-PCR | Pre-therapy | B7-H4 | 71/94(75.5) | OS | reported in text | High |
Kutun (2010) [33] | Turkey | I-IV | RT-PCR | pre-therapy | CK19 | 24/50(48.0) | OS | data extrapolated | Low |
CEA | 10/50(20.0) | OS | data extrapolated | ||||||
Matsusaka (2010) [34] | Japan | I-IV | CellSearch | pre-therapy | EpCAM/CK8/18/19 | 17/52(32.7) | RFS/OS | reported in text | Low |
intra-therapy wk2b | EpCAM/CK8/18/19 | 7/51(13.7) | RFS/OS | reported in text | |||||
intra-therapy wk4b | EpCAM/CK8/18/19 | 9/48(18.8) | RFS/OS | reported in text | |||||
Saad (2010) [35] | Egypt | I-IV | RT-PCR | pre-therapy | CK18 | 15/30(50.0) | RFS/OS | reported in text | High |
Arigami (2011) [36] | Japan | I-IV | RT-PCR | pre-therapy | B7-H3 | 48/95(50.5) | OS | reported in text | High |
Cao (2011) [37] | China | I-IV | RT-PCR | pre-therapy | survivin | 45/98(45.9) | RFS | reported in text | High |
Stein (2011) [38] | Germany | I-IV | RT-PCR | intra-therapy | S100A4 | 32/64(50.0) | RFS | data extrapolated | High |
Ayerbes (2012) [39] | Spain | I-IV | RT-PCR | intra-therapy | miR-200c | 28/52(53.8) | RFS/OS | reported in text | High |
Wang (2012) [40] | China | I-IV | RT-PCR | pre-therapy | miR-20a | 34/65(52.3) | OS | reported in text | High |
miR-17-5p | 33/65(50.8) | OS | reported in text | ||||||
Ito (2012) [41] | Japan | I-IV | ICC | pre-therapy | telomerase | 41/65(63.1) | OS | data extrapolated | High |
Arigami (2013) [42] | Japan | I-IV | RT-PCR | pre-therapy | STC2 | 43/93(46.2) | OS | reported in text | High |
Balgkouranidou (2013) [43] | Greece | I-IV | MSP | pre-therapy | mSOX17 | 43/73(58.9) | OS | reported in text | High |
Kang (2013) [44] | China | I-IV | RT-PCR | pre-therapy | hTERT | 118/118(100) | RFS/OS | reported in text | High |
Komatsu (2013) [45] | Japan | I-IV | RT-PCR | pre-therapy | miR-21 | 47/69(68.1) | OS | reported in text | High |
miR-17-5p | 38/69(55.1) | OS | data extrapolated | ||||||
miR-106a | 53/69(76.8) | OS | data extrapolated | ||||||
miR-106b | 56/69(81.2) | OS | data extrapolated | ||||||
Lee (2013) [46] | Korea | I-IV | RT-PCR | pre-therapy | mSEPT9 | 27/153(17.6) | RFS | data extrapolated | High |
Song (2013) [47] | China | I-IV | RT-PCR | post-therapy | miR-21 | 51/103(49.5) | OS | data extrapolated | High |
Uenosono (2013) [48] | Japan | I-IV | CellSearch | pre-therapy | EpCAM/CK8/18/19 | 16/148(10.8) | OS(R)c | reported in text | High |
16/148(10.8) | RFS(R)c | data extrapolated | |||||||
| Â | Â | Â | Â | Â | Â | 62/103(61.8) | OS(UR)c | data extrapolated | Â |